BIOMAT Database Logo BIOMAT Database Logo

A study of antitumor (phase II) and immunosuppressive effects of ICRF-159 in patients with metastatic melanoma. 1976

R E Bellet, and R B Catalano, and V G Danna, and D A Berd, and J Berkelhammer, and M J Mastrangelo

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008297 Male Males
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D011929 Razoxane An antimitotic agent with immunosuppressive properties. ICRF-159,ICRF-186,NSC-129943,Razoxane Mesylate, (R)-Isomer,Razoxane, (R)-Isomer,Razoxin,ICRF 159,ICRF 186,ICRF159,ICRF186,NSC 129943,NSC129943
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

R E Bellet, and R B Catalano, and V G Danna, and D A Berd, and J Berkelhammer, and M J Mastrangelo
Phase II study of ICRF-159 versus combination cis-dichlorodiammineplatinum(II) and DTIC in patients with disseminated malignant melanoma.
January 1978, Cancer treatment reports,
R E Bellet, and R B Catalano, and V G Danna, and D A Berd, and J Berkelhammer, and M J Mastrangelo
Phase II study of ICRF-159 in non-Hodgkin's lymphomas.
March 1978, Cancer treatment reports,
R E Bellet, and R B Catalano, and V G Danna, and D A Berd, and J Berkelhammer, and M J Mastrangelo
Phase II study of ICRF-159 (NSC-129943) in advanced colorectal carcinoma.
January 1975, Cancer chemotherapy reports,
R E Bellet, and R B Catalano, and V G Danna, and D A Berd, and J Berkelhammer, and M J Mastrangelo
Phase II evaluation of dibromodulcitol, ICRF-159, and maytansine for sarcomas.
August 1982, American journal of clinical oncology,
R E Bellet, and R B Catalano, and V G Danna, and D A Berd, and J Berkelhammer, and M J Mastrangelo
Phase II study of dianhydrogalactitol and ICRF-159 in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy.
January 1977, Cancer treatment reports,
R E Bellet, and R B Catalano, and V G Danna, and D A Berd, and J Berkelhammer, and M J Mastrangelo
in vitro effects of ICRF 159.
July 1973, British journal of cancer,
R E Bellet, and R B Catalano, and V G Danna, and D A Berd, and J Berkelhammer, and M J Mastrangelo
A phase II study of gefitinib in patients with metastatic melanoma.
August 2011, Melanoma research,
R E Bellet, and R B Catalano, and V G Danna, and D A Berd, and J Berkelhammer, and M J Mastrangelo
Phase II study of E7070 in patients with metastatic melanoma.
January 2005, Annals of oncology : official journal of the European Society for Medical Oncology,
R E Bellet, and R B Catalano, and V G Danna, and D A Berd, and J Berkelhammer, and M J Mastrangelo
Phase II study of thalidomide in patients with metastatic melanoma.
February 2004, Melanoma research,
R E Bellet, and R B Catalano, and V G Danna, and D A Berd, and J Berkelhammer, and M J Mastrangelo
Phase III study of ICRF-159 versus 5-FU in the treatment of advanced metastatic colorectal carcinoma.
January 1980, Cancer treatment reports,
Copied contents to your clipboard!